PolyPid (PYPD) Enterprise Value (2019 - 2026)
PolyPid (PYPD) posted Enterprise Value of -$9.1 million for Q1 2026, down 37.71% sequentially from -$6.6 million in Q4 2025, and down 272.67% YoY from $5.3 million in Q1 2025.
PolyPid (PYPD) Enterprise Value (2019 - 2026) Analysis & Trends
PolyPid has reported Enterprise Value for 8 years, with the latest figure at -$9.1 million in Q1 2026.
- Quarterly Enterprise Value fell 272.67% year-over-year to -$9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (down 272.67% YoY) and the FY2025 annual result came in at -$6.6 million, up 58.28% from the prior year.
- Enterprise Value retreated to -$9.1 million in Q1 2026 per PYPD's latest filing, from -$6.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.8 million in Q3 2023 and troughed at -$17.6 million in Q2 2025.
- A 5-year average of -$8.4 million and a median of -$6.9 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 88.8% in 2023, then slumped 444.3% in 2025.
- Over 5 years, Enterprise Value stood at -$9.1 million in 2022, then soared by 38.11% to -$5.6 million in 2023, then plunged by 181.85% to -$15.8 million in 2024, then soared by 58.28% to -$6.6 million in 2025, then tumbled by 37.71% to -$9.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$9.1 million, -$6.6 million, and -$9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 2.12 Bn |
| 10 | PolyPid | 113.74 Mn | 106.97 Mn | - | -6.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.77 Mn |
| Mar 31, 2026 | -9.08 Mn |
| Dec 31, 2025 | -6.60 Mn |
| Sep 30, 2025 | -9.86 Mn |
| Jun 30, 2025 | -17.63 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Dec 31, 2024 | -15.81 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -3.24 Mn |
| Mar 31, 2024 | -4.01 Mn |
| Dec 31, 2023 | -5.61 Mn |
| Sep 30, 2023 | -1.85 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -6.87 Mn |
| Dec 31, 2022 | -9.06 Mn |
| Sep 30, 2022 | -16.50 Mn |
| Jun 30, 2022 | -13.01 Mn |
| Mar 31, 2022 | -11.83 Mn |
| Dec 31, 2021 | -10.22 Mn |
| Sep 30, 2021 | -9.61 Mn |